Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity

• ClinicalTrials.gov Identifier: NCT04800159
• Recruitment Status: Recruiting
• First Posted: March 16, 2021
• Last Update Posted: March 16, 2021
• Sponsor: University of California, San Diego
• Collaborator: Center for Medicinal Cannabis Research
• Information provided by (Responsible Party): Scott Letendre, University of California, San Diego

Study Description

Brief Summary:

This study will address whether cannabis affects antiretroviral therapy (ART) drug concentrations, mood, and thinking. The project will have two phases. Phase 1 is an observational study, in which 120 people will be assessed to evaluate the effects of chronic cannabis use on ART drug concentrations, mood, and thinking. In Phase 2, the study will administer cannabis (or placebo) to 40 people to examine its acute effects on ART drug concentrations.

Condition or disease	Intervention/treatment	Phase
HIV; Cannabis Use	Drug: THC Cannabis; Drug: CBD Cannabis; Drug: Placebo	Phase 2

Detailed Description:

People with human immunodeficiency virus (HIV) commonly use cannabis but whether cannabis affects the antiretroviral therapy (ART) that treats HIV is not well known. Cannabis can inhibit the activity of enzymes that metabolize and eliminate ART drugs from the body, which could result in higher concentrations of ART drugs in the body. Cannabis may also affect the distribution of ART drugs into the brain, which could have both beneficial (e.g., better HIV control) and detrimental (e.g., toxicity) effects. The effects of cannabis may are likely influenced by factors like how much is used (e.g., light vs. heavy use) and the route of use (e.g., smoked vs. ingested). This study will address whether cannabis affects ART concentrations in blood and cerebrospinal fluid as well as mood, and thinking. The project will have two phases. Phase 1 is an observational study, in which 120 people will be assessed once to evaluate the effects of chronic cannabis use on ART drug concentrations, mood, and thinking. In Phase 2, the study will administer cannabis (or placebo) to 40 people to examine its acute effects on ART drug concentrations.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 40 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Intervention Model Description: The interventional component of the project (Phase 2) will have a randomized cross-over design that randomly assigns the order of the administration of the three study products (placebo, cannabis with higher concentration of tetrahydrocannabinol (THC) and lower concentration of cannabidiol (CBD), or cannabis with higher CBD concentration and lower THC concentration). The cannabis administration phase of this study will compare the study products to: 1) ART concentrations in blood and CSF and 2) measures of uridine 5'-diphospho-glucuronosyltransferase (UGT) activity.
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Masking Description: Participants will randomly receive one of the study products at each visit. All participants will receive all three of the study products. Allocation assignment of visits will be assigned using a randomization string provided by the statistician. The allocation schedule will be kept in the pharmacy and concealed from all other study personnel.
• Primary Purpose: Basic Science
• Official Title: Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity
• Actual Study Start Date: February 19, 2021
• Estimated Primary Completion Date: January 30, 2025
• Estimated Study Completion Date: April 30, 2025

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: THC Cannabis; 13.03% THC/ 0.13% CBD	Drug: THC Cannabis; Vaporization of cannabis; Other Name: Marijuana
Active Comparator: CBD Cannabis; 0.44% THC/ 12.32% CBD	Drug: CBD Cannabis; Vaporization of cannabis; Other Name: Marijuana
Placebo Comparator: Placebo; ≤ 0.01% THC/ ≤ 0.01% CBD	Drug: Placebo; Vaporization of placebo; Other Name: Marijuana with < 0.01% of THC and CBD

Outcome Measures

Primary Outcome Measures :

1. 1a i. Antiretroviral therapy (ART) drug concentration in blood [ Time Frame: Cross-sectional; measured before ART ingestion ]
   This will be done separately for participants who use ART drugs that are predominantly metabolized by cytochrome P450 (CYP) or uridine 5'-diphospho-glucuronosyltransferase (UGT) (estimated N=60 in each).
2. 1a ii. Cerebrospinal fluid (CSF)/plasma ratio of ART drug concentrations [ Time Frame: Cross-sectional; measured before ART ingestion ]
   This will be done separately for CYP and UGT groups (estimated N=60 in each).
3. 1a iii. Change in ART drug concentrations in blood [ Time Frame: 2 hours; measured before ART ingestion and at 2 hours after the ART ingestion ]
   This will be done separately for CYP and UGT groups (estimated N=60 in each).
4. 1a iv. Change in CSF/plasma ratio of ART drug concentrations [ Time Frame: 2 hours; measured before ART ingestion and at 2 hours after the ART ingestion ]
   This will be done separately for CYP and UGT groups (estimated N=60 in each).
5. 1b i. Effects of placebo, THC, and CBD on ART drug concentration [ Time Frame: 5 hours ]
   We will use a mixed effects model to assess effects of acute cannabis treatment (placebo, THC, or CBD: N=40) on the area under the time-drug concentration curve.
6. 1b ii. Effects of placebo, THC and CBD on the CSF/plasma ratio of ART drug concentrations [ Time Frame: 5 hours ]
   We will use a mixed effects model to assess effects of acute cannabis treatment (placebo, THC, or CBD: N=40) on CSF/plasma ratio of ART drug concentrations
7. 1b iii. Comparison between the effects of placebo and THC on ART pharmacokinetics and between the effects of placebo and CBD on ART pharmacokinetics [ Time Frame: 3 to 11 days ]
   Comparison of the the area under the time-concentration curve of ART pharmacokinetics for placebo and THC and placebo and CBD (n=40). The effect size will be measured as the standardized difference in mean outcomes between any two groups (Cohen's d).
8. 1b iv. Comparison between the effects of placebo and CBD on the CSF/plasma ratio of ART drug concentrations and between the effects of placebo and THC on the CSF/plasma ratio of ART drug concentrations [ Time Frame: 3 to 11 days ]
   Comparison of the the CSF/plasma ratio of ART drug concentrations with placebo and CBD and with placebo and THC (n=40). The effect size will be measured as the standardized difference in mean outcomes between any two groups (Cohen's d).
9. 2a. Effects of chronic cannabis use on the CSF/serum albumin ratio and P-glycoprotein (P-gp) expression. [ Time Frame: 3 to 11 days ]
   Multivariate linear regression will be used to regress markers of blood-brain barrier integrity and P-gp on cannabis use (n = 120), then ART drug concentrations on blood-brain barrier integrity and P-gp separately for the UGT and CYP groups
10. 2b. Examine the correlation between ART concentration in CSF and blood during placebo treatment compared to THC and CBD administration. [ Time Frame: 3 to 11 days ]
    We will use a mixed effects model to evaluate the effects of cannabis on the correlation between ART concentration in CSF and blood (n = 40).
11. 2c. Effects of THC or CBD on uridine 5'-diphospho-glucuronosyltransferase (UGT) activity compared to placebo. [ Time Frame: 3 to 11 days ]
    We will use a mixed effects model to examine the effects of drug treatment on UGT metabolism (n = 40).
12. 3a. i. Associations between CD4+ T-cell count and ART drug concentration. [ Time Frame: Up to 5 weeks: baseline to administration visits ]
    Multivariable linear regressions will be used for testing associations between CD4+ T-cell count and ART drug concentration (N=60 in each UGT and CYP groups).
13. 3a. ii. Associations between HIV DNA and ART drug concentration. [ Time Frame: Up to 5 weeks: baseline to administration visits ]
    Multivariable logistic regressions will be used for testing associations between HIV DNA and ART drug concentration (N=60 in each UGT and CYP groups).
14. 3b i. Effects of cannabis use on the relationship between ART and neurocognitive performance. [ Time Frame: 3 to 11 days ]
    The total cognitive outcome from the National Institutes of Health Toolbox will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates. Values range from 0 to 100 with lower values being worse.
15. 3b ii. Effects of cannabis use on the relationship between ART and depression. [ Time Frame: 3 to 11 days ]
    Depression (measured with the Beck Depression Inventory-II) will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates.
16. 3b iii. Effects of cannabis use on the relationship between ART and emotional health. [ Time Frame: 3 to 11 days ]
    The National Institutes of Health Toolbox-Emotional Battery outcome, Negative Affect, will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates. This measure ranges between 0 and 100 with higher values reflecting more Negative Affect.
17. 3b iv. Effects of cannabis use on the relationship between ART and emotional health. [ Time Frame: 3 to 11 days ]
    The National Institutes of Health Toolbox-Emotional Battery outcome, Social Satisfaction, will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates. This measure ranges between 0 and 100 with lower values reflecting worse Social Satisfaction.
18. 3b v. Effects of cannabis use on the relationship between ART and emotional health. [ Time Frame: 3 to 11 days ]
    The National Institutes of Health Toolbox-Emotional Battery outcome, Psychological Wellbeing, will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates. This measure ranges between 0 and 100 with lower values reflecting worse Psychological Wellbeing.
19. 3b vi. Effects of cannabis use on the relationship between ART and neurotoxicity. [ Time Frame: 3 to 11 days ]
    A measure of neurotoxicity (mitochondrial DNA) will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates.
20. 3b vii. Effects of cannabis use on the relationship between ART and neurotoxicity. [ Time Frame: 3 to 11 days ]
    A measure of neurotoxicity (8-hydroxydeoxyguanosine) will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates.
21. 3b viii. Effects of cannabis use on the relationship between ART and neurotoxicity. [ Time Frame: 3 to 11 days ]
    A measure of neurotoxicity (F2-isoprostane) will be regressed in multivariable models on ART drug concentration and cannabis use, their interaction, and known confounders and relevant covariates.

Secondary Outcome Measures :

1. 1b v. Comparison between the effects of THC and CBD on ART pharmacokinetics. [ Time Frame: 3 to 11 days ]
   Comparison of the treatment arm to the the area under the time-concentration curve of ART pharmacokinetics (n=40).
2. 1b vi. Comparison between the effects of THC and CBD on the CSF/plasma ratio of ART drug concentrations. [ Time Frame: 3 to 11 days ]
   Comparison of treatment arm to the CSF/plasma ratio of ART drug concentrations.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria for All Visits:

1. Age 18 or older;
2. Capacity to provide informed consent;
3. Presence of HIV infection by a standard diagnostic test;
4. On a stable ART regimen for at least 3 months;
5. Taking an ART drug that is metabolized by either cytochrome p450 (CYP) isozymes or by uridine 5'-diphospho-glucuronosyltransferase (UGT) isozymes; and
6. Willing to abstain from cannabis for at least 24 hours prior to the Phase 1 assessment.

Additional Inclusion Criteria for participation in Phase 2 (interventional):

1. Treatment with dolutegravir;
2. Use of cannabis in the past two years without a severe adverse reaction (e.g., disorientation, paranoia, or hallucinations). The two-year cutoff is to ensure exposure to modern cannabis, which is more likely to match the drug concentrations administered in this study;
3. Willing to refrain from driving or operating heavy machinery after the visit; and
4. Willing to abstain from cannabis for at least 48 hours prior to the cannabis administration visits.

Exclusion Criteria for All Visits:

1. Traumatic brain injury, including head injury with loss of consciousness for greater than 30 minutes or resulting in neurologic complications;
2. Dementia, including Alzheimer's disease;
3. History of stroke with residual neurologic sequelae;
4. History of seizure disorder with a seizure in the past year;
5. Severe psychiatric disorder (e.g., schizophrenia) that might make the person's participation in the study unsafe;
6. Substance or alcohol use disorder in the past 12 months;
7. Contraindications to lumbar puncture for those consenting to lumbar puncture (e.g., coagulopathy).

Additional Exclusion Criteria for participation in the cannabis administration visits:

1. Younger than 21 years (due to safety of cannabis in children and adolescents);
2. Respiratory condition that would be exacerbated by inhaling vaporized cannabis (e.g., asthma or chronic obstructive pulmonary disease) or limited lung capacity that would prevent the individual from performing the Foltin puff procedure;
3. History of cardiovascular disease, including myocardial infarction;
4. Uncontrolled hypertension with systolic blood pressure greater than 160 mm Hg or a diastolic blood pressure greater than 100 mm Hg prior to study product administration;
5. Resting pulse greater than 100 beats per minute prior to study product administration;
6. Pregnancy as determined by a human chorionic gonadotropin urine test, women who are lactating, or unwillingness to prevent pregnancy during the cannabis administration portion of the study (using birth control in women of child-bearing age). Acceptable methods of birth control are: oral contraceptive pills, diaphragm, condom, progestin implant, intrauterine contraceptive device, sterilization, etc;
7. Active opportunistic infection or malignancy requiring treatment;
8. CD4+ T-cell count less than 200 cells/µL;
9. Estimated glomerular filtration rate < 40 mL/minute, indicative of renal dysfunction;
10. Hepatic transaminases > 2 times the upper limit of normal;
11. Current severe depressive symptoms (BDI-II score ≥ 31) or suicidal ideation;
12. Known sensitivity to acetaminophen (the probe for UGT activity);
13. Current use of substances that could have adverse interactions with acetaminophen or cannabis (e.g., grapefruit juice).

Contacts and Locations

Contacts

Contact: Robert Bryan; 619-543-5000; hnrprecruitment@ucsd.edu

Locations

United States, California

Ucsd Hnrp-Cmcr; Recruiting

San Diego, California, United States, 92103

Contact: Robert Bryan 619-543-5000 hnrprecruitment@ucsd.edu

Sponsors and Collaborators

University of California, San Diego

Center for Medicinal Cannabis Research

Investigators

• Principal Investigator: Scott Letendre, MD; UCSD

More Information

• Responsible Party: Scott Letendre, Professor, University of California, San Diego
• ClinicalTrials.gov Identifier: NCT04800159
• Other Study ID Numbers: DA050491
• First Posted: March 16, 2021
• Last Update Posted: March 16, 2021
• Last Verified: March 2021

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Neurotoxicity Syndromes; Marijuana Abuse; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders; Nervous System Diseases; Poisoning